Condensed Consolidated Statements of Operations (Unaudited) - USD ($) |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2022 |
Sep. 30, 2021 |
Sep. 30, 2022 |
Sep. 30, 2021 |
|
Income Statement [Abstract] | ||||
Sales | $ 51,725 | $ 88,061 | ||
Operating expenses: | ||||
General and administrative | 540,716 | 591,468 | 962,853 | 1,002,078 |
Rent | 55,633 | 16,870 | 82,255 | 20,955 |
Salaries and Wages | 540,773 | 1,023,206 | 984,076 | 1,655,527 |
Stock Compensation | ||||
Professional services | 312,470 | 378,853 | 746,440 | 976,099 |
General and administrative | 1,449,592 | 2,010,397 | 2,775,624 | 3,654,659 |
Research and development | 4,000 | 196,872 | 176,643 | 196,872 |
Facility operations | 488,427 | 172,431 | 1,020,163 | 411,756 |
Depreciation | 408,232 | 257,772 | 933,461 | 612,275 |
Amortization | 367,500 | 146,500 | 735,000 | 146,500 |
Total operating expenses | 2,717,751 | 2,783,972 | 5,640,891 | 5,022,062 |
Net loss from operations | (2,666,026) | (2,783,972) | (5,552,830) | (5,022,062) |
Other income (expense): | ||||
Interest expense | (579,291) | (65,663) | (1,081,663) | (147,199) |
Interest expense - related parties | (3,522) | (3,522) | ||
Amortization of debt discount | (2,136,389) | (4,176,389) | (236,364) | |
Financing costs | (109,953) | |||
Change in fair value of derivative liability | (18,241,000) | (16,927,000) | ||
Change in fair value of warrant liability | (39,000) | 1,876,000 | ||
Forgiveness of PPP loan | 103,200 | |||
Loss due to fire | (863,117) | (863,117) | ||
Total other income (expense) | (21,862,319) | (65,663) | (21,175,691) | (390,316) |
Loss before income taxes | (24,528,345) | (2,849,635) | (26,728,521) | (5,412,378) |
Provision for income taxes | ||||
Net loss | (24,528,345) | (2,849,635) | (26,728,521) | (5,412,378) |
Amortization of beneficial conversion feature on Preferred shares | (42,500) | (1,341,948) | (184,000) | (817,376) |
Accretion on Preferred shares | (278,500) | (557,000) | ||
Redemption and exchange of Series D Preferred shares | (5,792,947) | |||
Dividends | (55,427) | (360,225) | (157,654) | (360,225) |
Net loss available for common stockholders | $ (24,904,772) | $ (4,551,808) | $ (27,627,175) | $ (12,382,926) |
EARNINGS PER SHARE (Basic and diluted) | $ (0.03) | $ (0.00) | $ (0.04) | $ (0.02) |
WEIGHTED AVERAGE SHARES OUTSTANDING (Basic and diluted) | 731,616,343 | 603,775,024 | 675,370,057 | 594,359,747 |
X | ||||||||||
- Definition Amortization of beneficial conversion feature on preferred shares No definition available.
|
X | ||||||||||
- Definition Forgiveness of paycheck protection program loan. No definition available.
|
X | ||||||||||
- Definition General and administrative expenses. No definition available.
|
X | ||||||||||
- Definition Loss due to fire No definition available.
|
X | ||||||||||
- Definition Redemption and exchange of series D preferred shares No definition available.
|
X | ||||||||||
- Definition Rent No definition available.
|
X | ||||||||||
- Definition Stock compensation No definition available.
|
X | ||||||||||
- Definition Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
X | ||||||||||
- Definition The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of amortization expense attributable to debt issuance costs. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
X | ||||||||||
- Definition The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition Facility expenses incurred related to gas and oil produced and sold during the reporting period. Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
|
X | ||||||||||
- Definition Amount of expense (income) related to adjustment to fair value of warrant liability. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
X | ||||||||||
- Definition Amount of interest expense incurred on a debt or other obligation to related party. No definition available.
|
X | ||||||||||
- Definition Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. No definition available.
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- Definition A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
X | ||||||||||
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|